Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
15 04 2019
Historique:
received: 22 04 2018
revised: 11 09 2018
accepted: 25 09 2018
pubmed: 12 10 2018
medline: 10 7 2019
entrez: 11 10 2018
Statut: ppublish

Résumé

Pathogenic variants in BRCA1 and BRCA2 only explain the underlying genetic cause of about 10% of hereditary breast and ovarian cancer families. Because of cost-effectiveness, multigene panel testing is often performed even if the clinical utility of testing most of the genes remains questionable. The purpose of our study was to assess the contribution of rare, deleterious-predicted variants in DNA repair genes in familial breast cancer (BC) in a well-characterized and homogeneous population. We analyzed 113 DNA repair genes selected from either an exome sequencing or a candidate gene approach in the GENESIS study, which includes familial BC cases with no BRCA1 or BRCA2 mutation and having a sister with BC (N = 1,207), and general population controls (N = 1,199). Sequencing data were filtered for rare loss-of-function variants (LoF) and likely deleterious missense variants (MV). We confirmed associations between LoF and MV in PALB2, ATM and CHEK2 and BC occurrence. We also identified for the first time associations between FANCI, MAST1, POLH and RTEL1 and BC susceptibility. Unlike other associated genes, carriers of an ATM LoF had a significantly higher risk of developing BC than carriers of an ATM MV (OR

Identifiants

pubmed: 30303537
doi: 10.1002/ijc.31921
pmc: PMC6587727
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1962-1974

Informations de copyright

© 2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Références

Genome Res. 2001 May;11(5):863-74
pubmed: 11337480
Nat Genet. 2002 Jan;30(1):97-101
pubmed: 11731797
Exp Dermatol. 2003 Oct;12(5):529-36
pubmed: 14705792
Nat Genet. 2006 Aug;38(8):873-5
pubmed: 16832357
Hum Mutat. 2006 Nov;27(11):1122-8
pubmed: 16958054
Nat Genet. 2007 Feb;39(2):165-7
pubmed: 17200668
Br J Cancer. 2008 Apr 22;98(8):1457-66
pubmed: 18349832
Hum Mutat. 2008 Nov;29(11):1342-54
pubmed: 18951461
Am J Hum Genet. 2009 Oct;85(4):427-46
pubmed: 19781682
Genome Res. 2010 Jan;20(1):110-21
pubmed: 19858363
Bioinformatics. 2010 Mar 1;26(5):589-95
pubmed: 20080505
Nat Genet. 2010 May;42(5):410-4
pubmed: 20400964
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Breast Cancer Res. 2010;12(6):R109
pubmed: 21182766
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Breast Cancer Res. 2011 Jan 18;13(1):R6
pubmed: 21244692
Cancer Res. 2011 Mar 15;71(6):2222-9
pubmed: 21285249
Hum Mutat. 2011 Jun;32(6):E2176-88
pubmed: 21618343
Breast Cancer Res. 2011 Jul 25;13(4):R73
pubmed: 21787400
Cancer. 2012 Mar 1;118(5):1387-96
pubmed: 21837677
Nat Med. 2011 Nov 20;17(12):1646-51
pubmed: 22101766
J Community Genet. 2011 Jun;2(2):53-69
pubmed: 22109790
Hum Mutat. 2012 Apr;33(4):674-80
pubmed: 22241545
Am J Hum Genet. 2012 Apr 6;90(4):734-9
pubmed: 22464251
Brief Bioinform. 2013 Mar;14(2):178-92
pubmed: 22517427
J Med Genet. 2012 Oct;49(10):618-20
pubmed: 23054243
Curr Protoc Hum Genet. 2013 Jan;Chapter 7:Unit7.20
pubmed: 23315928
Breast Cancer Res. 2013 Feb 28;15(1):R17
pubmed: 23448497
Oncogene. 2014 Oct 2;33(40):4803-12
pubmed: 24141787
Nucleic Acids Res. 2014 Jan;42(Database issue):D980-5
pubmed: 24234437
Nat Genet. 2014 Mar;46(3):310-5
pubmed: 24487276
Biomark Med. 2014;8(4):589-603
pubmed: 24796624
Breast Cancer Res. 2014 Jun 03;16(3):R58
pubmed: 24894818
Cancer Discov. 2014 Jul;4(7):804-15
pubmed: 25050558
N Engl J Med. 2014 Aug 7;371(6):497-506
pubmed: 25099575
Am J Respir Crit Care Med. 2015 Mar 15;191(6):646-55
pubmed: 25607374
Nat Genet. 2015 May;47(5):512-7
pubmed: 25848748
N Engl J Med. 2015 Jun 4;372(23):2243-57
pubmed: 26014596
Eur Respir J. 2015 Aug;46(2):474-85
pubmed: 26022962
J Hum Genet. 2015 Oct;60(10):597-603
pubmed: 26178433
BMC Cancer. 2016 Jan 12;16:13
pubmed: 26758370
J Clin Oncol. 2016 May 1;34(13):1455-9
pubmed: 26786923
Curr Protoc Hum Genet. 2016 Apr 01;89:8.16.1-8.16.23
pubmed: 27037489
Breast Cancer Res Treat. 2016 Sep;159(2):385-92
pubmed: 27544226
J Med Genet. 2016 Dec;53(12):800-811
pubmed: 27595995
Breast Cancer Res. 2016 Nov 9;18(1):111
pubmed: 27829436
Nucleic Acids Res. 1989 Oct 25;17(20):8390
pubmed: 2813076
BMC Med Genomics. 2017 Feb 15;10(1):8
pubmed: 28202063
Haematologica. 2017 Aug;102(8):e293-e296
pubmed: 28495916
Front Immunol. 2017 May 01;8:449
pubmed: 28507545
Am J Med Genet A. 2017 Sep;173(9):2511-2516
pubmed: 28688171
Eur J Hum Genet. 2017 Dec;25(12):1345-1353
pubmed: 29255180
Lancet. 1996 Jun 22;347(9017):1713-27
pubmed: 8656904

Auteurs

Elodie Girard (E)

Inserm, Paris, France.
Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Séverine Eon-Marchais (S)

Inserm, Paris, France.
Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Robert Olaso (R)

Centre National de Recherche en Génomique Humaine, Institut de Biologie François Jacob, CEA, Evry, France.

Anne-Laure Renault (AL)

Inserm, Paris, France.
Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Francesca Damiola (F)

Département de Biopathologie, Centre Léon Bérard, Lyon, France.

Marie-Gabrielle Dondon (MG)

Inserm, Paris, France.
Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Laure Barjhoux (L)

Département de Biopathologie, Centre Léon Bérard, Lyon, France.

Didier Goidin (D)

Life Sciences and Diagnostics Group, Agilent Technologies France, Les Ulis, France.

Vincent Meyer (V)

Centre National de Recherche en Génomique Humaine, Institut de Biologie François Jacob, CEA, Evry, France.

Dorothée Le Gal (D)

Inserm, Paris, France.
Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Juana Beauvallet (J)

Inserm, Paris, France.
Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Noura Mebirouk (N)

Inserm, Paris, France.
Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Christine Lonjou (C)

Inserm, Paris, France.
Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Juliette Coignard (J)

Inserm, Paris, France.
Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.
Université Paris Sud, Paris, France.

Morgane Marcou (M)

Inserm, Paris, France.
Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Eve Cavaciuti (E)

Inserm, Paris, France.
Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Céline Baulard (C)

Centre National de Recherche en Génomique Humaine, Institut de Biologie François Jacob, CEA, Evry, France.

Marie-Thérèse Bihoreau (MT)

Centre National de Recherche en Génomique Humaine, Institut de Biologie François Jacob, CEA, Evry, France.

Odile Cohen-Haguenauer (O)

Hôpital Saint-Louis, Paris, France.

Dominique Leroux (D)

Département de Génétique, CHU de Grenoble, Hôpital Couple-Enfant, Grenoble, France.

Clotilde Penet (C)

Consultation d'Oncogénétique, Institut Jean-Godinot & ICC Courlancy, Reims, France.

Sandra Fert-Ferrer (S)

Service de Génétique, Centre Hospitalier de Chambéry, Chambéry, France.

Chrystelle Colas (C)

Département de Génétique Groupe Hospitalier Pitié-Salpêtrière, APHP, Paris, France.
Service de Génétique, Institut Curie, Paris, France.

Thierry Frebourg (T)

Département de Génétique, Hôpital Universitaire de Rouen, Rouen, France.

François Eisinger (F)

Institut Paoli Calmette, Département d'Anticipation et de Suivi des Cancers, Oncogénétique Clinique, Institut Paoli-Calmettes & Aix Marseille Université, Inserm, IRD, SESSTIM, Marseille, France.

Claude Adenis (C)

Service de Génétique, Centre Oscar-Lambret, Lille, France.

Anne Fajac (A)

Service d'Oncogénétique, Hôpital Tenon, Paris, France.

Laurence Gladieff (L)

Service d'Oncologie Médicale, Institut Claudius Regaud - IUCT-Oncopole, Toulouse, France.

Julie Tinat (J)

Département de Génétique, Hôpital Universitaire de Rouen, Rouen, France.

Anne Floquet (A)

Institut Bergonié, Bordeaux, France.

Jean Chiesa (J)

CHRU Hôpital Caremeau, Nîmes, France.

Sophie Giraud (S)

Service de Génétique, Hospices Civils de Lyon, Groupement Hospitalier EST, Bron, France.

Isabelle Mortemousque (I)

Service de Génétique, Hôpital Bretonneau, Tours, France.

Florent Soubrier (F)

Hôpital Tenon, Paris, France.

Séverine Audebert-Bellanger (S)

Département de Génétique Médicale en Pédiatrie CHU Brest, Hôpital Morvan, Brest, France.

Jean-Marc Limacher (JM)

Service d'Onco-hématologie, Hôpital Pasteur, Colmar, France.

Christine Lasset (C)

Université Claude Bernard Lyon 1, Villeurbanne; CNRS UMR 5558, Unité de Prévention et Epidémiologie Génétique, Lyon, Centre, Léon Bérard, France.

Sophie Lejeune-Dumoulin (S)

Service de Génétique Clinique Guy Fontaine, Hôpital Jeanne de Flandre, Lille, France.

Hélène Dreyfus (H)

Clinique Sainte Catherine, Avignon & CHU de Grenoble, Département de Génétique, Hôpital Couple-Enfant, Grenoble, France.

Yves-Jean Bignon (YJ)

Université Clermont Auvergne; Inserm, U1240, Centre Jean Perrin, Clermont-Ferrand, France.

Michel Longy (M)

Institut Bergonié, Bordeaux, France.

Pascal Pujol (P)

Service de Génétique Médicale et Oncogénétique, Hôpital Arnaud de Villeneuve, CHU Montpellier & INSERM 896, CRCM Val d'Aurelle, Montpellier, France.

Laurence Venat-Bouvet (L)

Service d'Oncologie Médicale, Hôpital Universitaire Dupuytren, Limoges, France.

Valérie Bonadona (V)

Université Claude Bernard Lyon 1, Villeurbanne; CNRS UMR 5558, Unité de Prévention et Epidémiologie Génétique, Lyon, Centre, Léon Bérard, France.

Pascaline Berthet (P)

Unité de Pathologie Gynécologique, Centre François Baclesse, Caen, France.

Elisabeth Luporsi (E)

Service de Génétique UF4128 CHR Metz-Thionville, Hôpital de Mercy, Metz, France.

Christine M Maugard (CM)

Hôpitaux Universitaires de Strasbourg, UF1422 Oncogénétique moléculaire, Laboratoire d'Oncobiologie & UF6948 Oncogénétique Evaluation familiale et suivi, Strasbourg, France.

Catherine Noguès (C)

Institut Paoli Calmette, Département d'Anticipation et de Suivi des Cancers, Oncogénétique Clinique, Institut Paoli-Calmettes & Aix Marseille Université, Inserm, IRD, SESSTIM, Marseille, France.

Capucine Delnatte (C)

Unité d'Oncogénétique, Centre René Gauducheau, Nantes, Saint Herblain, France.

Jean-Pierre Fricker (JP)

Unité d'Oncologie, Centre Paul Strauss, Strasbourg, France.

Paul Gesta (P)

Service d'Oncogénétique Régional Poitou-Charentes, Niort, France.

Laurence Faivre (L)

Institut GIMI, CHU de Dijon, Hôpital d'Enfants, Oncogénétique & Centre de Lutte contre le Cancer Georges François Leclerc, Dijon, France.

Alain Lortholary (A)

Service d'Oncologie Médicale, Centre Catherine de Sienne, Nantes, France.

Bruno Buecher (B)

Service de Génétique, Institut Curie, Paris, France.

Olivier Caron (O)

Gustave Roussy, Université Paris-Saclay, Département de Médecine Oncologique, Villejuif, France.

Marion Gauthier-Villars (M)

Service de Génétique, Institut Curie, Paris, France.

Isabelle Coupier (I)

Service de Génétique Médicale et Oncogénétique, Hôpital Arnaud de Villeneuve, CHU Montpellier & INSERM 896, CRCM Val d'Aurelle, Montpellier, France.

Nicolas Servant (N)

Inserm, Paris, France.
Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Anne Boland (A)

Centre National de Recherche en Génomique Humaine, Institut de Biologie François Jacob, CEA, Evry, France.

Sylvie Mazoyer (S)

Inserm, U1028, CNRS UMR5292, Centre de Recherche en Neurosciences de Lyon, France.

Jean-François Deleuze (JF)

Centre National de Recherche en Génomique Humaine, Institut de Biologie François Jacob, CEA, Evry, France.

Dominique Stoppa-Lyonnet (D)

Service de Génétique, Institut Curie, Paris, France.
Inserm, U830, Institut Curie, Paris, France.
Université Paris Descartes, Paris, France.

Nadine Andrieu (N)

Inserm, Paris, France.
Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Fabienne Lesueur (F)

Inserm, Paris, France.
Institut Curie, Paris, France.
Mines ParisTech, Fontainebleau, France.
PSL Research University, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH